Context: During a mass smallpox immunization campaign, vaccine may be exposed to ambient temperatures for extended periods of time.
Objective: To determine the viability of undiluted and 5x diluted DryVax smallpox vaccine after cycling vaccine in and out of refrigeration for 2 weeks, as might occur during an immunization campaign.
Design: Two vials of Dryvax vaccine were reconstituted as per manufacturer's instructions (1x) and two vials were reconstituted using 5x the recommended diluent (5x).
Background: The outbreak of monkeypox in the Midwestern United States during June 2003 marks the first documented human infection in the Western Hemisphere. Consistent with those in outbreaks in Africa, most cases in this outbreak were associated with febrile rash illness. We describe a cluster of monkeypox in a family with a spectrum of clinical illness, including encephalitis, and outline the laboratory confirmation of monkeypox.
View Article and Find Full Text PDF